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A biosimilar is intended to be highly similar to a reference biologic such that any differences in quality
attributes (i.e., molecular characteristics) do not affect safety or efﬁcacy. Achieving this benchmark for
biologics, especially large glycoproteins such as monoclonal antibodies, is challenging given their com-
plex structure and manufacturing. Regulatory guidance on biosimilars issued by the U.S. Food and Drug
Administration, Health Canada and European Medicines Agency indicates that, in addition to a
demonstration of a high degree of similarity in quality attributes, a reduced number of nonclinical and
clinical comparative studies can be sufﬁcient for approval. Following a tiered approach, clinical studies
are required to address concerns about possible clinically signiﬁcant differences that remain after lab-
oratory and nonclinical evaluations. Consequently, a critical question arises: can clinical studies that
satisfy concerns regarding safety and efﬁcacy in one condition support “indication extrapolation” to
other conditions? This question will be addressed by reviewing the case of a biosimilar to inﬂiximab that
was approved recently in South Korea, Europe, and Canada for multiple indications through extrapola-
tion. The principles discussed should also apply to biosimilars of other monoclonal antibodies that are
approved to treat multiple distinct conditions.
© 2014 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).1. Introduction
As innovator biologics lose patent protection, biopharmaceuti-
cal companies have sought to develop biosimilar versions of these
agents. Several biosimilars have been approved, particularly in
Europe. These include molecules such as epoetin, ﬁlgrastim and
growth hormone which have relatively low molecular weights in
distinction to monoclonal antibodies [1].
Biologics are difﬁcult to copy exactly due to their structural
complexity and the nature of the cell culture systems used in their
manufacture. Thus, biosimilars, particularly larger proteins with
post-translational modiﬁcations, can be engineered to be highly: þ1 519 931 5278.
. Feagan).
Ltd on behalf of The International A
y-nc-nd/3.0/).similar but not identical to their reference biologics. Requirements
for approval of a biosimilar by the U.S. Food and Drug Administra-
tion (FDA), Health Canada and European Medicines Agency (EMA)
include extensive in vitro studies demonstrating similarity to a
reference biologic in terms of quality attributes, as well as
nonclinical and clinical studies demonstrating comparable phar-
macokinetics (PK), efﬁcacy, safety, and immunogenicity [2e4].
Given that the clinical performance of the innovator biologic has
already been established, the nonclinical and clinical studies
required for approval of a biosimilar may be reduced comparedwith
the studies required for approval of the innovator biologic. The ap-
peal of developing a biosimilar is further enhanced by the possibility
of gaining approval for all indications held by the reference product
based on less extensive nonclinical data, andminimal clinical data in
only a subset of indications. The impact of such indicationlliance for Biological Standardization. This is an open access article under the CC BY-
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approved uses while others have many. FDA, Health Canada and
EMA have directed sponsors to justify requests for indication
extrapolation based on a number of considerations (Table 1) [2e4].
Providing a global perspective, the World Health Organization
(WHO) has also laid out guidelines for indication extrapolation [5].
Indication extrapolation may depend on a limited number of
issues for biologics when a single molecular target, mechanism of
action, and site of action exists across different indications and a
well-described pharmacokineticepharmacodynamic relationship
has been established, preferably on the basis of a biomarker rather
than clinical outcomes (e.g., recombinant human insulin and serum
glucose). In contrast, extrapolation for monoclonal antibodies
(mAbs) can be more challenging. A biosimilar to inﬂiximab known
as CT-P13 was recently approved in South Korea, Europe, and
Canada for multiple indications through extrapolation [6e10].
The innovator molecule inﬂiximab, a mAb directed against tu-
mor necrosis factor alpha (TNFa), is approved in many regions
around the world for use in adult patients with rheumatoid
arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA),
Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis
(Pso), as well as in pediatric patients with CD, and UC [11e13].
While TNFa is implicated in the pathophysiology of all these con-
ditions, their clinical manifestations are distinct. Furthermore, the
respective mechanisms of action, sites of action, PK, concomitant
medications, immunogenicity risk, and safety proﬁle of inﬂiximab
are different, or may be different. This article will address factors to
consider when evaluating indication extrapolation for biosimilars
with a special focus on inﬂiximab.
2. Regulatory basis for indication extrapolation
To date, CT-P13 and REMICADE® (Janssen Biotech, Inc. Horsham,
PA, United States) have been studied in comparative clinical trials in
RA and AS. In 2013, following endorsement by the Committee forTable 1
Regulatory considerations for indication extrapolation for biosimilars.
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patient population forMedicinal Products for Human Use (CHMP) in Europe, CT-P13, also
known as REMSIMA™ (Celltron, Inc., Incheon, Republic of Korea)
and INFLECTRA™ (Hospira, Inc. Lake Forest, IL, United States), was
approved by EMA for all indications held by inﬂiximab including
RA, AS, PsA, CD, UC, Pso, and pediatric CD and UC [7,8,14,15]. In
2014, the products were approved by Health Canada for RA, AS, PsA
and Pso but not CD or UC [9,10,16,17].
Comparisons of CT-P13 and inﬂiximab have been presented at
the European League Against Rheumatism Congress in 2013 [18], in
two publications [19,20], in two European Public Assessment Re-
ports (EPARs) for CT-P13 [7,8], the Product Monographs of
REMSIMA™ and INFLECTRA™ in Canada [9,10], and in the Sum-
mary Basis of Decision documents for REMSIMA™ and INFLEC-
TRA™ issued by Health Canada [16,17]. According to these sources,
CT-P13 and inﬂiximab exhibited similarity in most but not all of the
biochemical and bioactivity assays employed. The molecules also
exhibited similar PK, safety and efﬁcacy in AS, as well as similar
safety and efﬁcacy in RA [7,8,16,17,19,20] to the limited extent that
small to moderately sized trials are able to exclude differences.
The EPARs provide insight into the regulatory basis for the
indication extrapolation in Europe [7,8]. Even though differences
between CT-P13 and inﬂiximab were noted in certain sensitive
in vitro assays, EMA assigned more weight to other assays that it
considered more clinically relevant [7,8], and which demonstrated
similarity between CT-P13 and inﬂiximab. (These assays will be
described in more detail below.) EMA also judged RA to be a suf-
ﬁciently sensitive clinical model in which to detect potential dif-
ferences between CT-P13 and inﬂiximab [7,8]. Overall, EMA
concluded that the sponsor provided convincing evidence and
adequate scientiﬁc justiﬁcation to allow indication extrapolation
[7,8].
Health Canada had a different view of the sponsor's proposed
justiﬁcation, as extrapolation was allowed for PsA and Pso but not
CD or UC [9,10,16,17]. According to Health Canada, approval of CD or
UC could not be recommended due to the differences between CT-e pharmacokinetic/pharmacodynamic (PK/PD) data to bridge two or more
ent for extrapolation.
extrapolate clinical data to other indications where rationales are sufﬁciently
be justiﬁed based on: mechanism(s) of action; pathophysiological mechanism(s)
ions involved; safety proﬁle in the respective conditions and/or populations; and
e reference biologic drug.
ased on the overall evidence of comparability provided from the comparability
te justiﬁcation.
parability is based on PD and for the claimed indications different mechanisms
uncertainty exists), then applicants should provide relevant data to support
d clinical indications.
such extrapolations with a comprehensive discussion of available literature
tigen receptor(s) and mechanism(s) of action.
extrapolation should address, for example, the following issues for the tested
ns of use:
ndition of use for which licensure is sought. This may include the following:
(s) for each relevant activity/function of the product;
oncentration response, and pattern of molecular signaling upon engagement
);
tween product structure and target/receptor interactions;
pression of the target/receptor(s);
ution of the product in different patient populations; PD measures may provide
on the MOA;
d toxicities in each condition of use and patient population (including whether
related to the pharmacological activity of the product or to off-target activities);
ay affect the safety or effectiveness of the product in each condition of use and
which licensure is sought.
B.G. Feagan et al. / Biologicals 42 (2014) 177e183 179P13 and inﬂiximab observed in vitro, potential differences in the
mechanism of action of inﬂiximab in the conditions, and the
absence of clinical studies [16,17]. Meanwhile, debate continues in
the medical community about whether the data in RA and AS
provide an adequate foundation for extrapolation to other in-
dications [21e27].
3. Clinical considerations
When planning for indication extrapolation, FDA recommends
that sponsors “consider whether the tested condition of use is the
most sensitive in which to detect clinically meaningful differences
in safety (including immunogenicity) and effectiveness” [4]. The
following sections will discuss the sensitivity of RA and AS studies
comparing CT-P13 and inﬂiximab, and address the residual uncer-
tainty about safety and efﬁcacy in other conditions.
3.1. Clinical sensitivity
In the pivotal clinical comparability study, 606 patients with RA
who previously failed MTX were randomized to receive CT-P13 or
inﬂiximab at a single-dose level of 3 mg/kg at weeks 0, 2 and 6 and
only at an interval of every 8 weeks thereafter in combination with
MTX (12.5e25 mg/week) [20]. Methotrexate itself has clinical ac-
tivity in RA, and potentiates the activity of inﬂiximab [28] and other
TNF antagonists by reducing immunogenicity, increasing drug
concentrations and affecting mechanisms not targeted by the bi-
ologics. Accordingly, it remains a challenge to attribute levels of
response to one agent or the other when the agents are used in
combination. For this reason, the use of concomitant MTX, while
required for the treatment of RA, may confound a conclusion that
CT-P13 and inﬂiximab have similar potency and/or efﬁcacy. Hence,
a demonstration of comparability in RAmay not reﬂect outcomes in
PsA, CD, UC, or Pso which are often treated with inﬂiximab mon-
otherapy or in combination with drugs other than MTX (Table 2).
(Concomitant MTX may be used in PsA, but its use is not required.)Table 2
Indications and dosing guidelines for TNFa antagonists according to the product monog
Indication Inﬂiximab [13] Golimumab [56] Adal
RA 3 mg/kg at wk 0, 2, 6/ q8wk
(up to 10 mg/kg and/or q4wk)
(þMTX)
50 mg/month (þMTX) 40 m
JIA (not approved) (not approved) Up t
AS 5 mg/kg at wk 0, 2, 6/ q6-8wk 50 mg/month 40 m
PsA 5 mg/kg at wk 0, 2, 6/ q8wk
(±MTX)
50 mg/month (±MTX) 40 m
CD 5 mg/kg at wk 0, 2, 6/ q8wk
(up to 10 mg/kg) (±conventional
therapy)
(not approved) 160
wk 2
Pediatric CD
(9 y)
5 mg/kg at wk 0, 2, 6/ q8wk (not approved) 160
wk 2
UC 5 mg/kg at wk 0, 2, 6/ q8wk
(up to 10 mg/kg)
200 mg wk 0/ 100 mg
at wk 2/ 50 mg at wk 6,
q4wk (up to 100 mg q4wk)
160
wk 2
Pediatric UC
(6 y)
5 mg/kg at wk 0, 2, 6/ q8wk (not approved) (not
Pso 5 mg/kg at wk 0, 2, 6/ q8wk (not approved) 80 m
wk 1
RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; AS, ankylosing spondylitis; PsA
for nonapproval of speciﬁc indications may include the following: studies not performed
a Weight-based dosing.While similar efﬁcacy in AS was observed when CT-P13 and
inﬂiximabwere given as monotherapy (n¼ 250; efﬁcacy endpoints
were secondary to PK endpoints) [19], the approval of CT-P13 in AS
should not imply that extrapolation from RA to AS for future bio-
similars is appropriate.
Other questions remain as to whether RA is a sensitive indica-
tion for evaluating the clinical impact of differences between
products. In a recent publication, Lee proposed that indications
with the highest placebo-adjusted response rate are most appro-
priate for detecting differences between drugs [26]. This position is
based on the principle that sensitivity for detecting small differ-
ences between agents is optimized in situations where the signal-
to-noise ratio is highest. RA has been identiﬁed as having the
lowest placebo-adjusted response to inﬂiximab (for ACR20/50/70
endpoints), and Pso the highest (for PASI75) [26]. Taken together,
these considerations raise questions about extrapolation from RA
(least sensitive clinical endpoint; treated with inﬂiximab and MTX)
to other indications. Perhaps recognizing some of these consider-
ations, at least two developers are conducting biosimilar studies for
adalimumab in Pso [29,30].
3.2. Mechanisms of action
Whether a single indication can support broad extrapolation for
mAbs relies on, among other things, the commonality of mecha-
nisms of action across indications. Cytokines and hormones such as
epoetin, ﬁlgrastim, insulin, and growth hormone typically have a
single binding site, molecular target and mechanism of action as
well as an easily assessed biological readout. In contrast, mAbs have
Fc and Fab regions (the latter include the antigen-binding regions)
which participate in various biological activities (Table 3) [31e33].
For example, antigen neutralization requires only binding through
the Fab region, whereas antibody-dependent cell-mediated cyto-
toxicity (ADCC) requires binding to antigen through the Fab region
along with binding to Fcg receptors on effector cells through the Fc
region. Considerable uncertainty exists regarding the extent toraphs in Canada.
imumab [41] Etanercept [37] Certolizumab pegol [57]
g q2wk (±MTX) 50 mg/wk (±MTX) 400 mg at
wk 0, 2, 4/ 200 mg
q2wk (or 400 mg q4wk)
(±MTX)
o 40 mg q2wka (±MTX) Up to 50 mg/wka (not approved)
g q2wk 50 mg/wk 400 mg at
wk 0, 2, 4/ 200 mg
q2wk (or 400 mg q4wk)
g q2wk (±MTX) 50 mg/wk (±MTX) 400 mg
at wk 0, 2, 4/ 200 mg
q2wk (or 400 mg q4wk)
(±MTX)
mg at wk 0/ 80 mg at
/ 40 mg at wk 4, q2wk
(not approved) (not approved; approved
in US with dosing 400 mg
at wk 0, 2, 4/ 400 mg
q4wk)
mg at wk 0/ 80 mg at
/ 20 mg at wk 4, q2wk
(not approved) (not approved)
mg at wk 0/ 80 mg at
/ 40 mg at wk 4, q2wk
(not approved) (not approved)
approved) (not approved) (not approved)
g at wk 0/ 40 mg at
, q2wk
50 mg 2/wk for
3 months/ 50 mg/wk
(not approved)
, psoriatic arthritis; CD, Crohn's disease; UC, ulcerative colitis; Pso, psoriasis. Reasons
; studies yielded negative outcome; studies not accepted by regulatory authorities.
Table 3
Fab-mediated and Fc-mediated interactions of monoclonal antibodies [31e33].
Antibody domain Molecular target Biological activitiesa
Fab Soluble antigen Neutralization (inhibition of
receptor binding)
Transmembrane
antigen
Neutralization (inhibition of
receptor binding)
Inhibition of extracellular
domain shedding
Reverse signaling (apoptosis)
Fc FcgRI
FcgRII
FcgRIII
Activating functions:
ADCC
Endocytosis of immune complexes
(and antigen presentation for
RI and RIII)
Phagocytosis
Clearance
Inhibitory functions:
Inhibiting activation of B lymphocytes,
monocytes, mast cells, and basophils
FcRn Turnover
C1q complement CDC
a Each biological activity may be relevant to only a subset of molecular targets
shown.
B.G. Feagan et al. / Biologicals 42 (2014) 177e183180which the Fc domain of inﬂiximab contributes to mechanism of
action in different indications. In RA, inﬂiximab is thought to act
predominantly through the neutralization of soluble and trans-
membrane TNFa, whereas in other conditions such as CD, signaling
through membrane-associated forms of TNFa and Fcg receptor
(triggering apoptosis or ADCC) may play a more important role
[7,8,16,17,32,34,35]. EMA acknowledged such a separation of func-
tion, stating in its guidance that ADCC appears to be more impor-
tant in some indications than in others [2]. While the apoptotic
effects of CT-P13 and inﬂiximab were reportedly comparable, dif-
ferences between CT-P13 and inﬂiximab were observed in a sen-
sitive ADCC assay [7,8,16,17]. Accordingly, the comparative data
generated in RA may not support the assumption of comparable
efﬁcacy in all indications.
Signaling through the Fc region of mAbs also depends on the
nature of their Fc receptor targets. Binding of mAbs to FcgRIIIa is
affected by the valine (V)/phenylalanine (F) polymorphism of
FcgRIIIa amino acid 158, which in turn affects ADCC. The 158V form
of the receptor has higher afﬁnity for IgG1-Fc than the 158F form
[36]. Compared with inﬂiximab, CT-P13 exhibited reduced binding
in vitro to FcgRIIIa (V and F allotypes) as well as to NK cells isolated
from healthy donors and CD patients (dependent on FcgRIIIa ge-
notype V/V and V/F; no difference was observed with F/F genotype)
[7,8,18]. Differences in ADCC were observed when NK cells from CD
patients were used, according to donor genotype (as above) [7,8,18].
These results suggest that pivotal studies beyond RA as well as
studies in patients with FcgRIIIa polymorphismsmay bewarranted.
In its justiﬁcation for extrapolation to inﬂammatory bowel dis-
eases, EMA questioned the physiological relevance of ADCC assay
results using NK cells, and reported on several studies in which
similarity between CT-P13 and inﬂiximab was observed [7,8]. For
example, the difference in binding to NK cells was abrogated in the
presence of diluted CD patient serum. Also, ADCC was comparable
when peripheral blood mononuclear cells from CD patients (V/F or
F/F genotype), or whole blood from healthy donor or CD patients
was used as a source of effector cells. Other supportive data
included (but were not limited to) the induction of regulatory
macrophages and inhibition of T-cell proliferation (regardless of
FcgRIIIa donor cell genotype), wound healing in a colon epithelial
cell culture model, inhibition of pro-inﬂammatory cytokinesecretion from human intestinal epithelial cells, and inhibition of
soluble TNFa-induced apoptosis of human intestinal epithelial
cells. In contrast, Health Canada did not approve CD or UC in-
dications [9,10,16,17], possibly reﬂecting a more conservative
approach to extrapolation in Canada. Health Canada stated that
“differences in the ability of [CT-P13 and inﬂiximab] to induce ADCC
could not be ruled out” and that “ADCC cannot be ruled out as a
mechanism of action in the inﬂammatory bowel diseases” [16,17].
Finally, differences in clinical activity among TNFa antagonists
illustrate that activity in one indication cannot be relied upon to
predict activity in other indications (Table 2). For example, eta-
nercept is active in rheumatoid diseases but not inﬂammatory
bowel diseases, and is used at a different dose level in Pso [37,38].
Compared with inﬂiximab, etanercept exhibits a number of dif-
ferences in biochemical activity, including an inability to bind
monomeric TNFa [39], lower avidity binding to transmembrane
TNFa as well as less stable binding to both soluble TNFa and
transmembrane TNFa [39,40], reduced activity on cells bearing
transmembrane TNFa as well as reduced CDC, impaired reverse
signaling/apoptosis, and less potent ADCC (in a cell-line dependent
manner) [32]. As another example, adalimumab is used at different
dose levels in RA, AS and PsA than in CD and UC, as well as Pso
[32,41].
Taken together, these ﬁndings suggest that the structureeactivity
relationships of inﬂiximab are key to its range of clinical activities,
and that the molecular interactions and mechanisms of action
required for activity may not be common across all rheumatoid
diseases, inﬂammatory bowel diseases, and psoriasis.
3.3. Immunogenicity
Given the variety of minor differences in the drug product that
can impact immunogenicity, such as formulation, impurities, and
packaging, clinically signiﬁcant differences in immunogenicity be-
tween products are arguably impossible to exclude without clinical
trials. FDA and WHO recommend that to support indication
extrapolation, immunogenicity should be investigated in the pa-
tient population that carries the highest risk of an immune
response and immune-related adverse events [4,5]. As described
above, patients in the RA study comparing CT-P13 and inﬂiximab
received concomitant MTX. MTX suppresses the formation of anti-
drug antibodies (ADAs) to inﬂiximab [28] which may reduce the
sensitivity for detecting differences in immunogenicity between
the products as well as potential inhibitory effects of ADAs on
clinical response. Patients in the comparative study in AS were
treated with inﬂiximab or CT-P13 monotherapy; however, patients
with AS (as well as patients with RA treated with MTX) have his-
torically exhibited a lower incidence of ADAs to inﬂiximab than
patients with Pso, CD or UC [13,42,43]. Accordingly, AS and RA
should not be considered sensitive populations from which to
extrapolate immunogenicity data.
3.4. Safety
FDA has guided sponsors to be cautious about extrapolating
safety risk proﬁles of candidate biosimilars across indications
because patient populations for different indications may have
different co-morbidities and receive different concomitant medi-
cations [4]. Health Canada and EMA also identify safety proﬁle as an
important consideration for indication extrapolation [2,3].
Depending on the product attribute that accounts for a given safety
risk (e.g., impurity, off-target effect, target interaction, or pharma-
cological effect), potential differences between a biosimilar and the
reference biologic may impact some safety risks but not others.
Where clinical data are needed to address the possibility that
Table 4
Inﬂiximab clearance rates in different patient populations.
Population Concomitant therapy Mean inﬂiximab
clearancea (L/day)
Reference
B.G. Feagan et al. / Biologicals 42 (2014) 177e183 181product differences might impact a speciﬁc safety risk, those data
should be generated in the clinical setting (e.g., indication, dosing,
patient population) where that risk is more commonly manifest.
The terms of marketing authorization for REMICADE® (inﬂix-
imab) identify speciﬁc, albeit infrequent, adverse drug reactions
linked to speciﬁc indications, comorbid conditions, concomitant
therapies, and/or age groups [11e13]. For example, patients with
mild heart failure should use REMICADE® with caution based on
observed higher mortality and higher incidence of cardiovascular
adverse events in patients with moderate/severe heart failure who
received doses of 10 mg/kg and 5/10 mg/kg, respectively. Also, rare
cases of hepatosplenic T-cell lymphoma have occurred primarily in
patients with CD or UC who had received treatment with AZA or 6-
MP concomitantly with or immediately prior to REMICADE®. The
majority of cases involved adolescent or young adult males. Also,
malignancies, some fatal, have been reported among children, ad-
olescents and young adults who received treatment with TNFa-
blocking agents including REMICADE®. Approximately half of these
cases were lymphomas. The other cases represented a variety of
malignancies including rare ones usually associated with immu-
nosuppression and malignancies that are not usually observed in
children and adolescents. Most of the patients were receiving
concomitant immunosuppressants. The comparative studies of CT-
P13 conducted in RA and AS do not appear to cover all relevant
patient populations including pediatric patients and patients taking
immunosuppressants other than MTX. Accordingly, extrapolation
to patient populations and combination regimens for which safety
studies have not been conducted should be considered with
caution.
One may also question whether the limited safety database for
CT-P13 at the time of approval will be representative of the
beneﬁterisk proﬁle of the product in the post marketing setting. In
the pivotal RA study, the incidence of serious adverse events in
patients receiving CT-P13 and inﬂiximab up to week 54 was 14%
and 10%, respectively [7,8]. The imbalancewas attributed to cases of
tuberculosis and pneumonia, which the sponsor linked to risk
factors or pre-existing conditions in affected patients [7,8]. The risk
of infection associated with CT-P13 versus inﬂiximab remains un-
clear until future data can be generated. The sponsor committed to
monitoring serious infections, including TB, as well as rare adverse
reactions known to inﬂiximab in the post marketing setting
through registries [7,8].
Finally, even though REMICADE® (inﬂiximab) is approved for
use in RA, CD, and UC at dose levels up to 10 mg/kg (Table 2, which
covers the terms of market authorization in Canada), patients with
AS and RA treated with CT-P13 received dose levels of only 5 mg/kg
and 3 mg/kg, respectively. Because CT-P13 and inﬂiximab are
manufactured through independent processes, they may have
different product and process-related impurities [2e4]. Studies
examining safety outcomes at higher dose levels may bewarranted,
and adverse events in the post marketing setting should be
analyzed with attention to the associated dose levels. Notably,
while EMA approved CT-P13 for use in RA at all dose levels and
intervals approved for REMICADE®, Health Canada approved CT-
P13 for use in RA only at a dose level of 3 mg/kg every 8 weeks,
which was the dose level studied [9,10].RA MTX 0.26 [58]
AS (monotherapy) 0.27 [47]
UC Corticosteroids
± AZA/6-MP (ACT1, ACT2)
± 5-aminosalicylates (ACT2)
0.41 [59]
CD Corticosteroids
± 5-aminosalicylates,
6-MP/AZA, MTX
0.38 [45]
a Cross-study comparison may be confounded by dose levels, concomitant
medications, and assay variability.3.5. Pharmacokinetics
In a comparative PK study, patients with AS were randomized to
receive inﬂiximab or CT-P13 at a dose level of 5mg/kg at weeks 0, 2,
6, and then every 8 weeks thereafter [19]. Primary endpoints were
area-under-the-curve at steady-state (AUCSS) and maximum
steady-state serum concentration (Cmax) betweenweeks 22 and 30.Similarity in these parameters was observed [7,8,19]; however,
because single-dose PK, as recommended by Health Canada [3,44],
has not been reported, the comparability of important parameters
such as Cmax, AUCT, clearance and terminal t1/2 in a sensitive pop-
ulation is unclear.
Monoclonal antibodies are cleared through several pathways
(nonspeciﬁc catabolism, FcgR-mediated, target-mediated, and
immunogenicity-related pathways), and most antibodies demon-
strate nonlinear, dose-dependent pharmacokinetics [45,46].
Accordingly, single-dose PK comparability studies using low and
high-dose levels would be appropriate for comparing elimination
since the contribution of different elimination pathways differs at
different dose levels [46].
Previous studies have identiﬁed that inﬂiximab clearance varies
in different patient populations. For example, clearance in CD is
approximately 45% higher than in RA (Table 4). Clearance is also
affected by concomitant medication (e.g., MTX, 6-MP, and azathi-
oprine) [28,45] as well as ADAs [47]. As discussed above, patients
with AS treated with inﬂiximab are less prone to developing ADAs
than patients with Pso treated with inﬂiximab [13,47]. Given the
multiple pathways through which mAbs are cleared from the body,
the effects of concomitant drugs, differences in immunogenicity,
and previous observations with inﬂiximab discussed above,
comparative PK data from the repeated-dose study in AS may not
be reﬂective of PK in other indications.3.6. Sites of action
Inﬂiximab is active in various tissues and organ systems
including joints, axial skeleton, gastrointestinal tract, and skin.
However, the concentration of inﬂiximab required for clinical
effectiveness in each tissue is unknown. Inﬂiximab is distributed
primarily into the vascular compartment [13]; thus, drug levels
measured in serum may not be an adequate surrogate for drug
levels in target tissues [48]. Because all relevant target tissues have
not been evaluated by the comparative studies in RA and AS,
indication extrapolation for CT-P13 is problematic. The validity of
such extrapolation relies on the assumption that CT-P13 and
inﬂiximab achieve similar distribution to all affected tissues.
3.7. Pathophysiology of disease
Health Canada identiﬁes pathophysiological mechanisms of
disease as a point to consider in support of indication extrapolation.
RA, AS, PsA, CD, UC, and Pso are distinct conditions. Among these
conditions, there appear to be both similarities and differences in
the signaling pathways involved [22,49e54]. TNFa, a pro-
inﬂammatory cytokine, is implicated in all of them, and treat-
ment with TNFa antagonists has yielded positive outcomes. How-
ever, the contribution of TNFa to disease progression depends on
B.G. Feagan et al. / Biologicals 42 (2014) 177e183182the receptor interactions and cooperating pathways in speciﬁc
tissues. Also, TNFa is present in the body as a soluble form and a
transmembrane form. These forms interact with the receptors
TNFR1 and TNFR2, which themselves can be membrane-bound or
soluble [32,55]. The involvement of speciﬁc forms of TNFa and their
receptors in each disease is not fully understood.
RA, AS, PsA, CD, UC, and Pso exhibit variable responsiveness to
different TNFa antagonists (Table 2), implying potential differences
in disease pathophysiology, and/or differences in mechanisms of
action and tissue penetration of the drugs (see above). This disease
selectivity also applies to biologics directed against other targets.
For example, abatacept (targets CD80 and CD86), tocilizumab
(targets IL-6 receptor), and rituximab (targets CD20) have
demonstrated efﬁcacy in RA; however, they are not all universally
active in other conditions including AS, PsA, CD, UC, and Pso.
Collectively, these observations suggest that RA, AS, PsA, CD, UC,
and Pso do not share a single, common pathophysiology, thus
challenging the validity of indication extrapolation for agents that
treat these conditions.4. Conclusion
CT-P13 represents the ﬁrst biosimilar mAb approved in South
Korea, Europe, and Canada, and the ﬁrst example of a biosimilar
mAb granted indication extrapolation in these jurisdictions. Given
the considerations reviewed above, broad extrapolation of
comparative safety and efﬁcacy data for inﬂiximab to conditions
that have not been studied remains a challenge. Questions remain
as to whether PK, efﬁcacy and safety data for CT-P13 in AS and RA
can be extrapolated to, and provide adequate justiﬁcation for use in
PsA, CD, UC, and Pso, as well as pediatric patients with IBD. In this
relatively unexplored area of biosimilars, a more conservative
approach is warranted which would call for clinical trials in more
sensitive indications, as well as studies encompassing all relevant
mechanisms of action, sites of action, concomitant medications,
and PK scenarios. It remains that EMA, following a totality-of-
evidence approach, concluded that the beneﬁt-risk balance for
CT-P13 was positive in all studied and extrapolated indications
[7,8]. Health Canada approved CT-P13 in some extrapolated in-
dications (PsA, Pso) but not others (adult and pediatric CD and UC)
[9,10,16,17]. As biosimilar mAbs move through development and
regulatory review around the world, critical evaluation of the re-
sidual uncertainty in safety and efﬁcacy in extrapolated indications
will be key to ensuring that patients and healthcare providers can
continue to beneﬁt from all available treatment options.Conﬂict of interest
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